Streetbeat News

BCDA

BioCardia, Inc.

https://www.biocardia.com

Industry

Biotechnology

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Open

1.98

Mkt cap

8.5M

Volume

77K

High

2.01

P/E Ratio

-0.38

52-wk high

11.55

Low

1.84

Div yield

N/A

52-wk low

1.84

BioCardia, Inc. (NASDAQ:BCDA) is exploring the development of a new Phase III clinical trial protocol for its CardiAMP autologous cell therapy for heart failure treatment, based on recent interim results. The company is considering replacing the third tier 6MWD with a more objective endpoint, potentially leading to a successful trial for product registration in the US. BioCardia is also focusing on accelerating its pivotal program for CardiAMP in Chronic Myocardial Ischemia.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:17 am

U.S. stocks traded mostly lower with the Dow Jones falling 100 points. Energy shares jumped by 1.2% while utilities shares fell by 2%. America’s Car-Mart Inc reported weaker-than-expected earnings for its first quarter. Verb Technology shares shot up 139% after launching a technology integration with TikTok. Manchester United shares dropped 20% following a report suggesting the Glazer family will take the club off the market. BioCardia was down 29% after releasing interim efficacy results in the phase 3 pivotal CardiAMP cell therapy heart failure trial.

Portfolio Pulse from Lisa Levin

September 05, 2023 | 6:30 pm

The article lists the stocks that gained and lost the most during Tuesday's mid-day trading session. Among the gainers were Verb Technology Company, SIGNA Sports United, Novo Integrated Sciences, and Cellectar Biosciences. Among the losers were BioCardia, Trinseo, AERWINS Technologies, and 1847 Holdings. America's Car-Mart shares fell by 11.8% following weak quarterly earnings and the appointment of Doug Campbell as CEO.

Portfolio Pulse from Lisa Levin

September 05, 2023 | 5:34 pm

On Tuesday, 164 companies hit new 52-week lows. Notable companies include NextEra Energy, SenesTech, WeWork, and Tarena International. The largest move was seen by WeWork, with shares plummeting 3189.55% to hit a new 52-week low. Tarena International's shares had the biggest turnaround, rebounding 0.0% after reaching a new 52-week low.

Portfolio Pulse from Benzinga Insights

September 05, 2023 | 5:34 pm

US stocks traded mixed with the Nasdaq Composite turning higher and the Dow and S&P 500 falling. US factory orders fell by 2.1% in July. Verb Technology Company, Cellectar Biosciences, and GD Culture Group Limited saw their shares rise after various positive announcements. Manchester United, 1847 Holdings, and BioCardia saw their shares drop due to negative news.

Portfolio Pulse from Lisa Levin

September 05, 2023 | 4:16 pm

US stocks opened lower with the Nasdaq Composite falling around 50 points. Brady Corp reported better-than-expected Q4 results and increased its annual dividend. Verb Technology shares shot up 115% after launching a technology integration with TikTok. Shares of SIGNA Sports and GD Culture Group also rose significantly. TradeUP Acquisition, AERWINS Technologies, and BioCardia saw their shares drop.

Portfolio Pulse from Lisa Levin

September 05, 2023 | 1:54 pm

In Tuesday's pre-market session, several health care stocks saw significant movement. Helius Medical Tech, Cellectar Biosciences, RVL Pharmaceuticals, Aravive, WAVE Life Sciences, and Rani Therapeutics Hldgs saw increases ranging from 14.21% to 50.5%. Meanwhile, BioCardia, Longeveron Inc. - Subscription Right, Aditxt, electroCore, Axcella Health, and Trxade Health saw declines ranging from 12.05% to 20.4%.

Portfolio Pulse from Benzinga Insights

September 05, 2023 | 1:06 pm

BioCardia Inc's stock is plunging after the company released interim efficacy results for its phase 3 pivotal CardiAMP cell therapy heart failure trial. The results showed that the 250-patient randomized controlled study is unlikely to meet its primary three-tiered Finkelstein-Schoenfeld (FS) efficacy endpoint. The company's shares are down 23% at $0.60 during the premarket session.

Portfolio Pulse from Vandana Singh

September 05, 2023 | 12:50 pm

BioCardia has released interim efficacy results for its phase 3 pivotal CardiAMP cell therapy heart failure trial, causing its shares to drop.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 12:37 pm

Biocardia has announced interim efficacy results for its Phase 3 CardiAMP Cell Therapy Heart Failure Trial. The first-tier, all-cause death at 12 months was 5.6%, compared to 5.3% in the control group, a difference that was not statistically significant (P = 0.42).

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 11:20 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.